Focus Forward

Posted 01 November 2010 | By

The healthcare product industry remains one of the most closely watched and critically important in the world. Maintaining a balance between public health and private business interests for the overall public good is both challenging and vital. Consider some of the dynamics of current discussions: there is widespread concern about the cost of healthcare products even as the sector is regarded as key to economic growth; the public demands better and more-effective products but has less tolerance for risk; the review of new products must be based upon sound science and good data but scientific standards are lacking in some instances and data requirements may be unclear.

Categories:

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe